Showing 4341-4350 of 7279 results for "".
- Mindera Platform Named MedTech’s “Best New Technology Solution for Dermatology"https://practicaldermatology.com/news/mindera-platform-named-medtechs-best-new-technology-solution-for-dermatology/2460799/
- Henry Ford Innovations, Google Cloud, and Miracle Software Systems to Fund Innovations Focused on Health Inequitieshttps://practicaldermatology.com/news/henry-ford-innovations-google-cloud-and-miracle-software-systems-to-fund-innovations-focused-on-health-inequities/2460782/Entrepreneurs with ideas for reducing health inequities through the use of digital technology could garner $75,000 in cash and in-kind support toward developing their digital solution at Henry Ford Health System.
- Roflumilast Foam and Cream Show Promise in Multiple Skin Diseaseshttps://practicaldermatology.com/news/roflumilast-foam-and-cream-show-promise-in-multiple-skin-diseases/2460767/Roflumilast foam significantly improved both scalp and body psoriasis, with improvement as early as two weeks after treatment initiation, data presented at the 2021 AAD VMX show. Additionally, data presented in posters at the AAD VMX show that roflumilast foam is a safe, well-tolerated, and effec
- Almirall, MC2 Therapeutics Strike Deal to Distribute Wynzora in Europehttps://practicaldermatology.com/news/almirall-mc2-therapeutics-strike-deal-to-distribute-wynzora-in-europe/2460692/
- Breaking Business News: Evolus' Jeuveau Can Stay on U.S. Market For Nowhttps://practicaldermatology.com/news/breaking-business-news-evolus-jeuveau-can-stay-on-us-market-for-now/2460690/Evolus Inc. can remain for sale in the U.S. temporarily while an appeals court re-considers an import ban won by AbbVie Inc.’s Allergan that was slated to go into effect on Feb. 16, 2021, according to
- Potential Psoriasis Breakthrough: Bimekizumab Performs Well in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/potential-psoriasis-breakthrough-bimekizumab-performs-well-in-moderate-to-severe-plaque-psoriasis/2460684/Two new Phase 3 studies show that bimekizumab-treated psoriasis patients achieved superior levels of skin clearance compared to those who received placebo or ustekinumab. The safety profile of bimekizumab was consistent with earlier clinical studies with no new safety signals identified
- Injecting Nanoparticles Into Skin Cancers May Be An Alternative to Surgeryhttps://practicaldermatology.com/news/is-injecting-nanoparticles-into-skin-cancers-an-alternative-to-surgery/2460677/Yale researchers are developing a skin cancer treatment that involves injecting nanoparticles into the tumor, killing cancer cells with a two-pronged approach, as a potential alternative to surgery. The results are published in the Proceedings of the National Academy of Science
- Arcutis Moves Another Candidate Into Phase 3 Trialshttps://practicaldermatology.com/news/arcutis-moves-another-candidate-into-phase-3-trials/2460664/Roughly a week after announcing plans to initiate Phase 3 clinical trials for topical roflumilast cream (ARQ-151) in the treatment of atopic dermatitis (AD),
- MyHealthTeams' "Gaining Control with Psoriasis" Challenge Empowers Psoriasis Patients to Change Things Uphttps://practicaldermatology.com/news/myhealthteams-gaining-control-with-psoriasis-challenge-empowers-psoriasis-patients-to-change-things-up/2460663/
- Gene Sequencing May Quantify Risk of Skin Cancer Long Before Damage is Visiblehttps://practicaldermatology.com/news/gene-sequencing-may-quantify-risk-of-skin-cancer-long-before-damage-is-visible/2460644/New research sheds light on the carcinogenic effect of exposure to ultraviolet (UV) radiation, laying the groundwork for improvements in skin cancer risk stratification and prevention. In a study published&nbs